Their OLO device has gained FDA clearance for CBC tests, and the company is working to expand its use for other diagnostics, including monitoring chronic diseases, infectious diseases, and oncology.
The biotech has also partnered with pharma companies on trials that use its tech to track adverse events.
Its CEO, Yossi Pollak, told Fast Company last year that the company’s goal is to become “the standard of care for blood testing.”
As Haemanthus looks to make its mark in the diagnostics space, it will have to prove its technology works as advertised, especially given the skepticism lingering from Theranos’ fall. But with the market shifting to more personalized medicine and efficient clinical trials, there’s ample opportunity for new players with innovative solutions to succeed.
Only time will tell if Haemanthus can rise above its troubled roots and carve out a successful path in the competitive diagnostics industry.
The medtech company had a rollercoaster journey in recent years, going through multiple fundraising rounds before facing a setback in 2024. According to Israeli media reports, the company had to lay off 30% of its staff and is currently undergoing a restructuring phase.
Amidst this turmoil, other players in the industry are making significant strides. Researchers from the University of Colorado Boulder have made a breakthrough with a new device that could revolutionize bedside blood testing. Their innovative technology allows for the collection of small blood samples, isolation of particles using sound waves, and measurement of specific biomarkers within just 70 minutes – all within a handheld device.
The team behind this groundbreaking development is currently working on patent applications in collaboration with CU Boulder’s Venture Partners. They are also focused on further refining the technology to enable a wide range of tests to be conducted using this portable device.
This latest advancement underscores the relentless innovation and potential within the medtech sector. Despite the challenges faced by some companies, the industry as a whole continues to push boundaries and explore new frontiers in healthcare technology. Stay tuned for more updates on the latest developments in medtech and the exciting possibilities that lie ahead.
